Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared a recent article by Amrita Krishnan on X:

“SWOG Cancer Research Network S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (mmMRD) to direct Therapy Duration (DRAMMATIC) by Dr. Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski.”

Multiple Myeloma

Title: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapying Patients with Multiple Myeloma (mm) Using Minimal Residual Disease To direct Therapy Duration (DRAMMATIC study): SWOG s1803

Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski

Multiple Myeloma

Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma